Galera Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Galera Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10596
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Galera Therapeutics Inc (Galera Therapeutics) is a clinical-stage biotechnology company that discovers and develops novel cancer treatments. The company also concentrates on the prevention of radiation-induced toxicity including mucositis and the treatment of cancer. Its GC4419 is a selective small molecule superoxide dismutase enzyme mimetic that quickly converts superoxide free radical molecules to hydrogen peroxide and oxygen. Galera Therapeutic’s dismutase mimetics copies the human superoxide dismutase enzyme activities and overcome the deficiency. The company’s research and development unit concentrates on protection from normal tissue damage and direct anti-cancer therapy. Galera Therapeutics is headquartered in Malvern, Pennsylvania, the US.

Galera Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Galera Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Galera Therapeutics Raises USD70 Million in Series C Venture Financing 10
Galera Therapeutics Raises Additional USD15 Million in Series B Financing 12
Galera Therapeutics Raises Additional USD5 Million in Series B Financing 13
Galera Therapeutics Raises USD37 Million in Series B Financing 14
Galera Therapeutics Raises USD4.74 Million In Venture Financing 15
Galera Therapeutics Raises US$11 Million In Series A Financing 16
Asset Transactions 17
Galera Therapeutics Enters into Royalty Agreement with Clarus Ventures 17
Galera Therapeutics Inc – Key Competitors 18
Galera Therapeutics Inc – Key Employees 19
Galera Therapeutics Inc – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Product Approvals 21
Jul 31, 2017: Galera Therapeutics Announces Promising Innovative Medicines Designation from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency for GC4419 for the Reduction of Oral Mucositis in Head and Neck Cancer Patients 21
Clinical Trials 22
Jan 04, 2018: Data from Galera Therapeutics’ 223-Patient Phase 2b Clinical Trial of GC4419 to be Presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium 22
Dec 18, 2017: Galera Therapeutics Reports Statistically Significant Results in a 223-Patient Phase 2b Trial of GC4419 for Severe Oral Mucositis in Patients with Head and Neck Cancer 23
Jun 15, 2017: Galera Therapeutics Completes Enrollment in Phase 2b Clinical Trial with Lead Compound GC4419 for Treatment of Oral Mucositis 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Galera Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Galera Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Galera Therapeutics Raises USD70 Million in Series C Venture Financing 10
Galera Therapeutics Raises Additional USD15 Million in Series B Financing 12
Galera Therapeutics Raises Additional USD5 Million in Series B Financing 13
Galera Therapeutics Raises USD37 Million in Series B Financing 14
Galera Therapeutics Raises USD4.74 Million In Venture Financing 15
Galera Therapeutics Raises US$11 Million In Series A Financing 16
Galera Therapeutics Enters into Royalty Agreement with Clarus Ventures 17
Galera Therapeutics Inc, Key Competitors 18
Galera Therapeutics Inc, Key Employees 19

List of Figures
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Galera Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Indian Bank:企業の戦略・SWOT・財務情報
    Indian Bank - Strategy, SWOT and Corporate Finance Report Summary Indian Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • The Pep Boys – Manny, Moe & Jack of California:企業の戦略的SWOT分析
    The Pep Boys - Manny, Moe & Jack of California - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitor …
  • Immupharma Plc (IMM):製薬・医療:M&Aディール及び事業提携情報
    Summary ImmuPharma Plc (ImmuPharma) develops novel drugs for the treatment of serious medical conditions with unmet medical need. ImmuPharma develops drugs for the treatment of lupus, cancer, moderate to severe pain, highly resistant hospital-acquired infections such as methicillin-resistant staphyl …
  • Caixa Geral de Depositos SA:企業の戦略的SWOT分析
    Caixa Geral de Depositos SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Southern Maryland Electric Cooperative Inc:企業の戦略的SWOT分析
    Southern Maryland Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors an …
  • Ws Atkins Ltd
    Ws Atkins Ltd - Strategy, SWOT and Corporate Finance Report Summary Ws Atkins Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Buckeye Partners LP (BPL):企業の財務・戦略的SWOT分析
    Buckeye Partners LP (BPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Great Portland Estates Plc (GPOR):企業の財務・戦略的SWOT分析
    Great Portland Estates Plc (GPOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • O’Reilly Automotive, Inc. (ORLY):企業の財務・戦略的SWOT分析
    Summary O'Reilly Automotive Inc (O’Reilly) is a provider of automotive parts. The company offers automotive parts, tools, equipment, supplies and accessories. The company offers various services such as battery diagnostic testing; battery, wiper and bulb replacement; check and engine light code extr …
  • Ames Construction Inc:企業の戦略的SWOT分析
    Ames Construction Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Rubis SCA (RUI):石油・ガス:M&Aディール及び事業提携情報
    Summary Rubis SCA (Rubis) is an independent downstream company that carries out the storage, distribution and trading of bulk petroleum and chemical products. Its product portfolio includes fuel oil, liquefied petroleum gas (LPG), gasoline, diesel, home heating oil, chemical products, edible oils, m …
  • National Company KazMunayGas:企業の戦略的SWOT分析
    National Company KazMunayGas - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Step Pharma SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Step Pharma SAS (Step Pharma) is a biotechnology company that strives to discover and develop proprietary small molecule medicines for the treatment of auto-immune diseases. The company is developing a new class of oral nucleotide synthesis inhibitors against cytidine triphosphate synthase 1 …
  • SenGenix Inc:医療機器:M&Aディール及び事業提携情報
    Summary SenGenix Inc (SenGenix) is a medical device company that discovers and develops point-of-care diagnostic tests based on fluorescently responsive sensors for delivering patient data to clinicians. The company develops specific molecular sensors for each analyte in its POCT product portfolio. …
  • Republic Services, Inc.:戦略・SWOT・企業財務分析
    Republic Services, Inc. - Strategy, SWOT and Corporate Finance Report Summary Republic Services, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Leidos Holdings Inc:企業のM&A・事業提携・投資動向
    Leidos Holdings Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Leidos Holdings Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Eagle Cement Corporation (EAGLE):企業の財務・戦略的SWOT分析
    Eagle Cement Corporation (EAGLE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Extendicare Inc.:企業の戦略・SWOT・財務分析
    Extendicare Inc. - Strategy, SWOT and Corporate Finance Report Summary Extendicare Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Reliance Steel & Aluminum Co:企業の戦略・SWOT・財務情報
    Reliance Steel & Aluminum Co - Strategy, SWOT and Corporate Finance Report Summary Reliance Steel & Aluminum Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Caspian Energy Inc. (CKZ.H)-石油・ガス分野:企業M&A・提携分析
    Summary Caspian Energy Inc. (Caspian) is an independent upstream oil and gas company that explores for and develops hydrocarbon reserves, and produces oil and gas. Caspian and its subsidiaries hold interests in Aral Petroleum Capital LLP, which holds an exclusive license which entitles it to explore …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆